A study published in The Cerebellum provides initial experimental evidence that a single session of cerebellar ...

In this randomized clinical trial, home high-intensity aerobic training improved ataxia symptoms, fatigue, and aerobic fitness more than dose-matched home balance training among individuals with ...

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development.New th ...

Cerebellar ataxia results from dysfunction of the cerebellum, which is part of the brain that helps regulate and control movement and balance. People may experience changes in gait, speech, and eye ...

Brain imaging in MSA revealed that distinct cerebellar and medullary atrophy patterns were closely linked to cardiovascular autonomic dysfunction. A study published in June 2025 issue of European ...

This was a single-arm, interventional-, single-center, open-label prospective study. Patients with a history of probable MSA [15] were enrolled in the study (Table 1). All patients had some ...

Multiple sclerosis (MS) affects an estimated 2.3 million people worldwide. Approximately 80% of people with MS have inflammation in the cerebellum, the part of the brain that helps control movement ...

Early treatment with Ocrevus (ocrelizumab) may help protect the cerebellum, a region of the brain that plays a key role in motor coordination, cognitive function, and emotional regulation, from damage ...

Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, public reviews, and a provisional response from the authors. In this study, Daniel ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several companies—including Novartis, Scholar Rock and Biogen—progressing novel candidates through ...